For a decade, the brain was where pharmaceutical money generally went to die. Too complex, too poorly understood, too many failed trials. Nicolas Roberti, co-founding partner of the European BrainTech Fund, calls it a graveyard.
His argument is that the graveyard is about to reopen for business, and that the reason is not a single…
Stefan Eckhardt doesn't think much of pitch decks. He'd rather get a well-written email. And when a working prototype arrives in a founder meeting, what interests him isn't what it does — it's what it tells him about how the founders think.
Eckhardt is managing director of Callisto Health, the Berlin-based health-tech investor that led…



